Literature DB >> 16178500

Epidemiology, treatment, and prevention of community-acquired methicillin-resistant Staphylococcus aureus infections.

Todd J Kowalski1, Elie F Berbari, Douglas R Osmon.   

Abstract

Since first described In 1961, methicillin-resistant Staphylococcus aureus (MRSA) has become a common nosocomial pathogen. Substantial increases in MRSA infections among nonhospitalized patients are being reported. Methicillin-resistant S. aureus is the most common isolate from skin and soft tissue infections in selected centers in the United States. Community-acquired MRSA strains differ from nosocomial strains in clinically relevant ways, such as in their propensity to cause skin and soft tissue infection and severe necrotizing pneumonia. Clinicians in numerous specialties, particularly primary care physicians, will likely evaluate patients presentIng with community-acquired MRSA and should become familiar with the epidemiology and clinical characteristics of and evolving therapeutic and preventive strategies for this infection.

Entities:  

Mesh:

Year:  2005        PMID: 16178500     DOI: 10.4065/80.9.1201

Source DB:  PubMed          Journal:  Mayo Clin Proc        ISSN: 0025-6196            Impact factor:   7.616


  21 in total

1.  Prevalence and risk factors for MRSA nasal colonization among persons experiencing homelessness in Boston, MA.

Authors:  Jessica H Leibler; Casey León; Lena J P Cardoso; Jennifer C Morris; Nancy S Miller; Daniel D Nguyen; Jessie M Gaeta
Journal:  J Med Microbiol       Date:  2017-08       Impact factor: 2.472

2.  Nosocomial infections in ambulances and effectiveness of ambulance fumigation techniques in Saudi Arabia. Phase I study.

Authors:  Daifallah Alrazeeni; Mohammed S Al Sufi
Journal:  Saudi Med J       Date:  2014-11       Impact factor: 1.484

3.  Treatment and outcomes of infections by methicillin-resistant Staphylococcus aureus at an ambulatory clinic.

Authors:  John D Szumowski; Daniel E Cohen; Fumihide Kanaya; Kenneth H Mayer
Journal:  Antimicrob Agents Chemother       Date:  2006-11-20       Impact factor: 5.191

4.  A man with recurrent furunculosis.

Authors:  John M Embil; Zoe J Oliver; Michael R Mulvey; Elly Trepman
Journal:  CMAJ       Date:  2006-06-27       Impact factor: 8.262

5.  Severe skin and soft tissue infections and associated critical illness.

Authors:  Donald C Vinh; John M Embil
Journal:  Curr Infect Dis Rep       Date:  2006-09       Impact factor: 3.725

Review 6.  Prevention and control of infections in the home.

Authors:  John M Embil; Brenda Dyck; Pierre Plourde
Journal:  CMAJ       Date:  2009-05-26       Impact factor: 8.262

Review 7.  Incidence, characteristics, and outcomes of patients with bone and joint infections due to community-associated methicillin-resistant Staphylococcus aureus: a systematic review.

Authors:  K Z Vardakas; I Kontopidis; I D Gkegkes; P I Rafailidis; M E Falagas
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2013-01-20       Impact factor: 3.267

8.  Identifying exposure targets for treatment of staphylococcal pneumonia with ceftobiprole.

Authors:  Keith A Rodvold; David P Nicolau; Thomas P Lodise; Mohammed Khashab; Gary J Noel; James B Kahn; Mark Gotfried; Sara A Murray; Susan Nicholson; Somvadee Laohavaleeson; Pamela R Tessier; G L Drusano
Journal:  Antimicrob Agents Chemother       Date:  2009-05-18       Impact factor: 5.191

9.  In vitro 24-hour time-kill studies of vancomycin and linezolid in combination versus methicillin-resistant Staphylococcus aureus.

Authors:  Shveta Rani Singh; Alfred E Bacon; David C Young; Kimberly A Couch
Journal:  Antimicrob Agents Chemother       Date:  2009-07-27       Impact factor: 5.191

10.  Pharmacodynamic characterization of ceftobiprole in experimental pneumonia caused by phenotypically diverse Staphylococcus aureus strains.

Authors:  Somvadee Laohavaleeson; Pamela R Tessier; David P Nicolau
Journal:  Antimicrob Agents Chemother       Date:  2008-04-14       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.